ACA
LGND icon

Aptus Capital Advisors’s Ligand Pharmaceuticals LGND Stock Holding History

Aptus Capital Advisors’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,723
Closed -$1.08M – 314
2018
Q4 		$1.08M Buy
+12,723
New +$1.36M 0.28% 63

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return

Aptus Capital Advisors's LGND Position: Q1 2019 in Review

Aptus Capital Advisors sold out of Ligand Pharmaceuticals (LGND) in Q1 2019, closing a stake of 12,723 shares — an estimated $1.08M sold.

Aptus Capital Advisors first reported a position in LGND in Q4 2018 and held it in 1 quarter. The position peaked at $1.08M in Q4 2018. 330 funds tracked by Wall St. Rank hold LGND as of Q1 2019.

  • Aptus Capital Advisors reported no remaining Ligand Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Aptus Capital Advisors sold 12,723 Ligand Pharmaceuticals shares in Q1 2019, an estimated $1.08M.
  • Aptus Capital Advisors first reported a position in Ligand Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Aptus Capital Advisors's Ligand Pharmaceuticals position peaked at $1.08M in Q4 2018.
  • 330 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2019.

Based on Aptus Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.